signed a licensing agreement with the government of Israel to commercialize oligosaccharide elicitors, compounds that elicit immune responses from plants. * Novo Nordisk A/S, of Bagsvaerd, Denmark, and Bio-Intermediair, of Groningen, Netherlands, entered into a manufacturing agreement for the production of monoclonal antibodies...Bio-Intermediair also recently broke ground on a $C35 million manufacturing facility in Montreal. * Oxford Asymmetry, of Oxford, U.K., which specializes in the

Also, Metra entered into a definitive agreement to acquire Osteo Sciences Corp...It's Sugen's first extension into dermatology. * Texas Biotechnology Corp., of Houston, will provide data from its Novastan (brand of argatroban) trials in heparin-induced thrombocytopenia to Synthelabo, of Paris, which will pay Texas Biotechnology up to $2.5 million for the information

Interneuron estimates the cost for the remaining shares to be $7 million to $8 million. * Lidak Pharmaceuticals, of La Jolla, Calif., started two Phase II studies in HIV patients evaluating Lidakol as a topical treatment for Kaposi's sarcoma cutaneous lesions and Molluscum contagiosum. * Procept Inc., of Cambridge, Mass., said Thursday it registered to sell 2.2 million shares in a public offering...Trials of the antibody ultimately are expected to include 130 patients and 20 sites. (c) 1997

The original collaboration was in September 1994. * Medarex Inc., of Annandale, N.J., said published in vivo studies demonstrate its Bispecific technology stimulated a potent immune response against targeted antigens, causing a vaccine-like effect. * North American Biologicals Inc., of Boca Raton, Fla., intends to raise $60 million through the sale of convertible subordinated notes, subject to market and other conditions...Also, the company changed its name to NABI, and the common stock will

Pimagedine is designed to block formation of advanced glycosylation end-products (AGE), whose accumulation has been linked to diabetes and other age-related diseases

The court instructed Cambridge to pay a 1 percent royalty on net sales, and damages equal to 1 percent royalty for the pre-license period...subsidiary, relating to the sale and promotion of its TRAx CD4 and CD8 microtiter plate, an enzyme immunoassay used for enumeration of CD4 T lymphocytes. * Metra Biosystems Inc., of Mountain View, Calif., got U.S

In November the company raised the other $9 million, mostly through the sale of convertible notes. * Immunomedics Inc., of Morris Plains, N.J., said it will present its colorectal cancer imaging agent, CEA-Scan, for review to an FDA advisory committee on Feb. 16, 1996...An advisory committee on Oct. 17, 1995, failed to recommend approval of the product, which is an antibody fragment of a mouse monoclonal antibody against the tumor marker, carcinoembryonic antigen. (c) 1997 American Health

The agreement covered development of antisense drugs to prevent coronary artery restenosis following coronary angioplasty...The drug's safety was demonstrated in a 60-patient study in Argentina. * Xoma Corp., of Berkeley, Calif., selected a lead compound and several alternates to move out of the research phase of its antifungal development program...The company hopes to submit an investigational new drug application for the lead compound, Mycoprex, by the end of 1996. (c) 1997 American Health

Levitt developed technology to identify genes responsible for controlling bronchial hyperresponsiveness associated with asthma, and at Magainin he will create an asthma research program. * Paracelsian Inc., of Ithaca, N.Y., and the National Cancer Institute entered into a letter of intent to collaborate on Phase I and II studies of Paracelsian's PN355 and related compounds for cancer and HIV...The drugs is designed to block the binding of gp120 to the CD4 protein. * QLT PhotoTherapeutics Inc., of

The payments are for development and commercialization of an HIV protease inhibitor designed by Vertex called VX-478. * Protein Design Labs Inc., of Mountain View, Calif., has entered into a collaboration with a Japanese pharmaceutical company to humanize a mouse monoclonal antibody for potential use in treating infectious diseases

and Watson Pharmaceuticals Inc. _ to co-promote Eldepryl in the U.S. The drug is marketed as a treatment for Parkinson's disease. * NPS Pharmaceuticals Inc., of Salt Lake City, completed two studies of Norcalcin, which is being developed for treatment of primary and secondary hyperparathyroidism (HTP...Further analysis of the data is under way. * VIMRx Pharmaceuticals Inc., of Stamford, Conn., received final approval in Thailand to test its antiviral agent, VIMRxyn (synthetic hypericin), in HIV

The company was formed in 1994 and its research is based on an understanding of the transcriptional factors and biochemical signals that control gene expression in vascular endothelial cells. * BioCryst Pharmaceuticals Inc., of Birmingham, Ala., started a Phase I/II dose-escalation study using an oral formulation of BCX-34 to treat cutaneous T-cell lymphoma, T-cell leukemia and other T-cell cancers...The company plans to use the technology with its HIV immunogen and in other areas. * Houston

the other is in Type II diabetics with elevated cholesterol levels. * Atrix Laboratories Inc., of Fort Collins, Colo., said it filed a 510(k) premarket notification with the FDA seeking authorization to market a dental product, the Atrisorb Barrier for Guided Tissue Regeneration...With the news, the company said SmithKline Beecham, of London, extended its financial and technical support of the program. * Gilead Sciences Inc., of Foster City, Calif., said its collaborative partner, the

SciClone Pharmaceuticals Inc., of San Mateo, Calif., said its board of directors approved a stock repurchase program of up to 1 million shares because it believes the shares are undervalued and represent a good investment opportunity

It also exercised its option to reacquire certain marketing and distribution rights to the product in some countries where regulatory approvals have not been received. * SciClone Pharmaceuticals Inc., of San Mateo, Calif., said its board of directors approved a stock repurchase program of up to 1 million shares because it believes the shares are undervalued and represent a good investment opportunity

The approach is designed to stimulate cytotoxic T lymphocytes to attack tumor cells...It relates to statements made about the approval prospects of RespiGam

Aronex Pharmaceuticals Inc., of The Woodlands, Texas, and HealthCare Ventures settled a lawsuit related to lock-up agreements affecting redemption of warrants...As part of the deal Abbott will have worldwide rights to patented Medivir compounds, including H2G, for herpes indications, and non- nucleoside reverse transcriptase inhibitors for AIDS...Medivir will receive undisclosed research and development support, milestone payments and royalties on sales. * Sequus Pharmaceuticals Inc., of Menlo Park

OraVax Inc., of Cambridge, Mass., said a Phase I study in Switzerland of its UreAB oral vaccine antigen to battle Helicobacter pylori showed the treatment is safe...The first trial, initiated last month at Johns Hopkins University, of Baltimore, is using the AAV vector to deliver CFTR gene to cells of the nose and lung

The product uses the company's DepoFoam drug delivery designed to reduce toxicity of the antibiotic. * OraVax Inc., of Cambridge, Mass., said a Phase I study in Switzerland of its UreAB oral vaccine antigen to battle Helicobacter pylori showed the treatment is safe...The first trial, initiated last month at Johns Hopkins University, of Baltimore, is using the AAV vector to deliver CFTR gene to cells of the nose and lung